Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Horizon Investment Services LLC

Horizon Investment Services LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 83.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,759 shares of the biopharmaceutical company’s stock after selling 23,707 shares during the period. Horizon Investment Services LLC’s holdings in Halozyme Therapeutics were worth $228,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $60,054,000. Raymond James Financial Inc. acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at $21,838,000. Vanguard Group Inc. boosted its holdings in Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after buying an additional 251,711 shares in the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Halozyme Therapeutics by 60.0% during the fourth quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company’s stock worth $31,112,000 after purchasing an additional 243,940 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now directly owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. This represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HALO. Piper Sandler lifted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company dropped their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Trading Down 1.0 %

Shares of Halozyme Therapeutics stock opened at $63.84 on Friday. The company has a 50-day moving average of $59.16 and a two-hundred day moving average of $54.88. The stock has a market cap of $7.89 billion, a PE ratio of 18.61, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.